



OPEN ACCESS

EDITED AND REVIEWED BY
Gianni Ciofani,
Italian Institute of Technology (IIT), Italy

*CORRESPONDENCE

Hao Tang,
✉ tangpku_zzuhao@zzu.edu.cn
Ruiqin Li,
✉ lirqin@yeah.net
Hongtao Zhang,
✉ zhtzzu@zzu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 20 May 2025

ACCEPTED 30 June 2025

PUBLISHED 15 July 2025

CITATION

Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2025) Correction: Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery.
Front. Bioeng. Biotechnol. 13:1631667.
doi: 10.3389/fbioe.2025.1631667

COPYRIGHT

© 2025 Wang, Wang, Xiao, Cai, Xing, Tang, Li and Zhang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery

Yingying Wang^{1,2†}, Baiyan Wang^{1†}, Yangfan Xiao², Qingchun Cai³, Junyue Xing², Hao Tang^{2*}, Ruiqin Li^{4*} and Hongtao Zhang^{5,6,7,8*}

¹Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China, ²National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China, ³Department of Clinical Lab, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China, ⁴Academy of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, China, ⁵Blood Purification Center, The People's Hospital of Zhengzhou University, Zhengzhou, China, ⁶Blood Purification Center, Henan Provincial People's Hospital, Zhengzhou, China, ⁷Institute of Nephrology, Mathura, Henan, China, ⁸Department of Nephrology Henan Provincial People's Hospital, Zhengzhou, China

KEYWORDS

baicalin, lung cancer, gene therapy, miR-34a, hydrophobic modification

A Correction on

Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery

by Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2023). *Front. Bioeng. Biotechnol.* 11:1290413. doi: 10.3389/fbioe.2023.1290413

In the published article, there was an error in Western blot of [Figure 4C](#) as published. An extra GAPDH band image was included in the original [Figure 4C](#). The corrected Western blot of [Figure 4C](#) and its caption FIGURE 4 BA-PEI/miR-34a induced apoptosis of tumor cell A549. (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. appear below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 4
BA-PEI/miR-34a induced apoptosis of tumor cell A549. **(A)** Cell apoptosis analysis using flow cytometry, based on the control, miR-34a, PEI, BAPEI, PEI/miR-34a, and BA-PEI/miR-34a. **(B)** Quantitative analysis of **(A)**. **(C)** Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. **(D)** Quantitative analysis of **(C)**. * $p < 0.05$; ** $p < 0.01$; ns, not significant.